Anti‐HDV reflex testing in HBsAg ‐positive subjects: An efficacious strategy to identify HDV infection
Liver International · 2024-01 · 44 (1) · 148-154
DOI: 10.1111/liv.15746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 03.10.2023. Verfasst von Valentina Cossiga und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Diseases of the Liver and Biliary System Unit, University of Naples "Federico II", Naples, Italy. Hauptthemen laut MEDLINE: Hepatitis Antibodies, Hepatitis B Surface Antigens. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims The prevalence of HDV infection in HBsAg carriers is about 9.9% in Italy. However, the real prevalence is underestimated because the anti‐HDV test is not performed routinely in all HBsAg carriers. The aim of this study was to compare the prevalence and the absolute number of HDV infection identified in HBsAg‐positive subjects tested at University Hospital Federico II before and after the introduction of anti‐HDV reflex testing.
Methods
From January to December 2022, reflex test for the detection of total HDV antibodies was performed in all HBsAg‐positive subjects tested at University Hospital Federico II. The control group consisted of all the HBsAg‐positive subjects tested at the same laboratory in 2019, before the implementation of anti‐HDV reflex testing. Sera were evaluated with ADVIA Centaur HBsAgII Qualitative, Liaison Murex HBsAg Quantitative and Liaison Murex Total Anti‐HDV Qualitative.
Results
Before reflex testing, anti‐HDV had been tested in 16.4% (84/512) of HBsAg‐positive subjects, while after its implementation, 100% (484/484) of HBsAg‐positive patients was tested for anti‐HDV. The anti‐HDV positive prevalence was lower than before the introduction of reflex test (10.7% vs. 16.6%) but the absolute number of anti‐HDV positive patients increased (14 vs. 52 subjects). HDV‐RNA was detectable in 26 (53%) of 49 tested subjects.
Conclusions
Our data showed that the implementation of anti‐HDV reflex testing increased the diagnoses of HDV infection. In this setting, due to the approval of specific anti‐HDV drugs, a reflex test for anti‐HDV should be implemented to early identify patients with HBV/HDV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, Diseases of the Liver and Biliary System Unit, University of Naples "Federico II", Naples, Italy.
- Department of Translational Medical Science, University of Naples "Federico II", Naples, Italy.
- Department of Public Health, Division of Hepato-Bilio-Pancreatic, Minimally Invasive and Robotic Surgery, University of Naples "Federico II", Naples, Italy.
ORCID-Profile: Valentina Cossiga, Maria Guarino, Filomena Morisco
Zitieren
APA
Cossiga, V., Brusa, S., Montalti, R., De Conte, A., Jannuzzi, G., Ranieri, L., Sorrentino, R., Vallefuoco, L., Pignata, L., Guarino, M., Portella, G., & Morisco, F. (2024). Anti‐HDV reflex testing in HBsAg ‐positive subjects: An efficacious strategy to identify HDV infection. Liver International, 44(1), 148-154. https://doi.org/10.1111/liv.15746
Vancouver
Cossiga V, Brusa S, Montalti R, De Conte A, Jannuzzi G, Ranieri L, et al. Anti‐HDV reflex testing in HBsAg ‐positive subjects: An efficacious strategy to identify HDV infection. Liver International. 2024;44(1):148-154. doi:10.1111/liv.15746
BibTeX
@article{Cossiga2024,
author = {Cossiga, Valentina and Brusa, Stefano and Montalti, Roberto and De Conte, Annachiara and Jannuzzi, Giuseppe and Ranieri, Luisa and Sorrentino, Rosanna and Vallefuoco, Luca and Pignata, Luca and Guarino, Maria and Portella, Giuseppe and Morisco, Filomena},
title = {Anti‐HDV reflex testing in HBsAg ‐positive subjects: An efficacious strategy to identify HDV infection},
journal = {Liver International},
year = {2024},
volume = {44},
number = {1},
pages = {148--154},
doi = {10.1111/liv.15746}
}
EUVIMED